Registered Randomized Trials Comparing Generic and Brand-Name Drugs: A Survey-Reference-Cited by-同舟云学术

Registered Randomized Trials Comparing Generic and Brand-Name Drugs: A Survey

Published:2016-08 Issue:8 Volume:91 Page:1021-1034
ISSN:0025-6196
Container-title:Mayo Clinic Proceedings
language:en
Short-container-title:Mayo Clinic Proceedings

Author:

Flacco Maria Elena,Manzoli Lamberto,Boccia Stefania,Puggina Anna,Rosso Annalisa,Marzuillo Carolina,Scaioli Giacomo,Gualano Maria Rosaria,Ricciardi Walter,Villari Paolo,Ioannidis John P.A.

Publisher

Elsevier BV

Subject

General Medicine

Reference65 articles.

1. A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study;Dunne;BMC Pharmacol Toxicol,2013

2. Brand name versus generic warfarin: a systematic review of the literature;Dentali;Pharmacotherapy,2011

3. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis;Kesselheim;JAMA,2008

4. Branded versus generic clopidogrel in cardiovascular diseases: a systematic review;Caldeira;J Cardiovasc Pharmacol,2013

5. Generic versus brand-name drugs used in cardiovascular diseases;Manzoli;Eur J Epidemiol,2016

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of NOACS in high-risk patients with atrial fibrillation in Saudi Arabia: Perspectives on improving patient care;Expert Review of Cardiovascular Therapy;2021-03-04

2. Emotional tones in scientific writing: comparison of commercially funded studies and non-commercially funded orthopedic studies;Acta Orthopaedica;2020-12-02

3. Pharmacokinetics and Generic Drug Switching: A Regulator’s View;Clinical Pharmacokinetics;2020-06-17

4. Are Generic Drugs Used in Cardiology as Effective and Safe as their Brand-name Counterparts? A Systematic Review and Meta-analysis;Drugs;2020-04-11

5. The Portuguese generic medicines market: What’s next?;Health Policy;2020-04